Rectangle Created with Sketch.

About Hoshi

Canadian medical cannabis expertise meets European opportunity

Hoshi International is a European focused, fully integrated medical cannabis company with strategic assets along the entire value chain including cultivation, processing and distribution of dry flower and oil derivatives to the emerging European medical cannabis market. Founded by a group of cannabis entrepreneurs who were pioneers in establishing the regulated cannabis markets in Canada, the first G7 country to legalize cannabis worldwide. Supported by their 15+ years of experience in the Canadian and international markets, Hoshi is uniquely positioned to exploit the European market opportunity as it possesses a deep understanding of how to operate within strict but constantly evolving regulatory frameworks. Leveraging best in class cannabis industry IP, business intelligence, data, and experience, Hoshi is establishing itself as a leading provider of cannabis and derivative products to the emerging European market.

With a population of 748 million and a yearly healthcare spend exceeding €2.1 trillion, Europe is poised to become the largest global market for medical cannabis products. A lack of legal infrastructure to supply the local legal medical cannabis industry has created a shortage of GMP/GACP grade medical product. Hoshi is one of a few companies positioned to supply domestically produced, and hence tariff-free cannabis products to this massive, high growth market. Hoshi has been granted provisional licenses for vertically integrated medical cannabis operations in Portugal and Malta focused on importing, cultivating, processing, and exporting cannabis products.

Our Team

Hoshi Management

Responsible for obtaining, operating, and divesting over 15 cannabis licenses encompassing a broad spectrum of regulated aspects of the cannabis industry in Canada and abroad.

Hoshi Advisory Board

Rectangle Created with Sketch.
Group 573 Created with Sketch.

Overview

Hoshi Asset Overview

Cultivation

  • Conditionally licensed cultivation & extraction facility in Portugal
  • Both Greenhouse and Outdoor cultivation, with over 15 hectares of cultivation area
  • GACP, GMP licensed Q1 2022
  • 14,500 Kilograms annual production capacity by 2024

Manufacturing & Processing:

  • Manufacturing & downstream processing laboratory in Malta (GMP Licensed Q4 2021)

Distribution:

  • Export UK distribution through affiliate (June 2021)
  • Import and distribution subsidiary in Poland
  • German distribution agreement (16,000 pharmacies)